Oculis Holding Investor Relations Material

Oculis Holding AG is a global biopharmaceutical company focused on developing innovative treatments for eye diseases. The company's product pipeline includes several advanced-stage candidates designed to address significant unmet needs in ophthalmology. Notable among these are OCS-01, a topical eye drop for diabetic macular edema and post-cataract surgery inflammation, OCS-02, a topical biologic targeting dry eye disease and uveitis, and OCS-05, aimed at neuro-ophthalmic conditions such as acute optic neuritis and glaucoma. The company is headquartered in Zug, Switzerland, and its shares are listed on the Nasdaq.